← TrialMatch
HomeTrials

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironm

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

Condition(s)Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
StatusRecruiting
Study typeObservational
SummaryThis is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma
Who can participateInclusion Criteria: * Diagnosis of nodal and extranodal Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphomas (including low-grade transformed lymphomas; double and triple hit; 11q aberration; not otherwise specified) after 1st January 2019 * Presence of one MYC translocation or gain of copies (GCN: \> 3 copies in more than 30% of the nuclei) or amplification evaluated by FISH * Availability of immunohistochemical analysis of CD10, Bcl6, MUM1, Bcl2, Myc, Ki67 * Have received curative treatment (e.g. R-CHOP, R DA EPOCH, intensified "Burkitt like" chemotherapies) as first-line therapy * Histological material of adequate size and quality to perform histological review with any additional investigations (immunohistochemistry, FISH and other molecular analysis). A FFPE block must be provid
Ages18 Years to 79 Years
SexAll
Lead sponsorFondazione Italiana Linfomi - ETS
LocationsAlessandria, Italy; Ancona, Italy; Bari, Italy; Brescia, Italy; Candiolo, Italy; Castelfranco Veneto, Italy (+14 more sites)
Start date2025-05-05
NCT IDNCT06588205
Official listinghttps://clinicaltrials.gov/study/NCT06588205

🔍 Search all trials →